We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 8 februari 2018

Leukemia - Table of Contents alert Volume 32 Issue 2

If you are unable to see the message below, click here to view.
Leukemia
TABLE OF CONTENTS

Volume 32, Issue 2 (February 2018)

In this issue
Perspective
Review
Original Articles
Letters to the Editor
Corrigenda

Also new
AOP
 
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Subscribe
Advertisement
nature.com webcasts

Springer Nature presents a custom webcast on: Applications of imaging flow cytometry for the diagnosis of leukaemia

Date: Thursday, February 22, 2018 Time: 8AM PST | 11AM EST | 4PM GMT | 5PM CEST 

Register for the webcast and live Q&A session 

Sponsored by: 
MilliporeSigma
 

Perspective

Top

Perspective on Diamond–Blackfan anemia: lessons from a rare congenital bone marrow failure syndrome OPEN

K M Sakamoto and A Narla

Leukemia 2018 32: 249-251; advance online publication, September 8, 2017; 10.1038/leu.2017.314

Full Text

Review

Top

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond OPEN

C S Chim, S K Kumar, R Z Orlowski, G Cook, P G Richardson, M A Gertz, S Giralt, M V Mateos, X Leleu and K C Anderson

Leukemia 2018 32: 252-262; advance online publication, November 16, 2017; 10.1038/leu.2017.329

Abstract | Full Text

Original Articles

Top

ACUTE MYELOID LEUKEMIA

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients

D Beck, J A I Thoms, C Palu, T Herold, A Shah, J Olivier, L Boelen, Y Huang, D Chacon, A Brown, M Babic, C Hahn, M Perugini, X Zhou, B J Huntly, A Schwarzer, J-H Klusmann, W E Berdel, B Wörmann, T Büchner, W Hiddemann, S K Bohlander, L B To, H S Scott, I D Lewis, R J D'Andrea, J W H Wong and J E Pimanda

Leukemia 2018 32: 263-272; advance online publication, July 4, 2017; 10.1038/leu.2017.210

Abstract | Full Text

The MLL recombinome of acute leukemias in 2017 OPEN

C Meyer, T Burmeister, D Gröger, G Tsaur, L Fechina, A Renneville, R Sutton, N C Venn, M Emerenciano, M S Pombo-de-Oliveira, C Barbieri Blunck, B Almeida Lopes, J Zuna, J Trka, P Ballerini, H Lapillonne, M De Braekeleer, G Cazzaniga, L Corral Abascal, V H J van der Velden, E Delabesse, T S Park, S H Oh, M L M Silva, T Lund-Aho, V Juvonen, A S Moore, O Heidenreich, J Vormoor, E Zerkalenkova, Y Olshanskaya, C Bueno, P Menendez, A Teigler-Schlegel, U zur Stadt, J Lentes, G Göhring, A Kustanovich, O Aleinikova, B W Schäfer, S Kubetzko, H O Madsen, B Gruhn, X Duarte, P Gameiro, E Lippert, A Bidet, J M Cayuela, E Clappier, C N Alonso, C M Zwaan, M M van den Heuvel-Eibrink, S Izraeli, L Trakhtenbrot, P Archer, J Hancock, A Möricke, J Alten, M Schrappe, M Stanulla, S Strehl, A Attarbaschi, M Dworzak, O A Haas, R Panzer-Grümayer, L Sedék, T Szczepański, A Caye, L Suarez, H Cavé and R Marschalek

Leukemia 2018 32: 273-284; advance online publication, July 13, 2017; 10.1038/leu.2017.213

Abstract | Full Text

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress OPEN

S Masciarelli, E Capuano, T Ottone, M Divona, S De Panfilis, C Banella, N I Noguera, A Picardi, G Fontemaggi, G Blandino, F Lo-Coco and F Fazi

Leukemia 2018 32: 285-294; advance online publication, August 4, 2017; 10.1038/leu.2017.231

Abstract | Full Text

Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML

A Stengel, W Kern, M Meggendorfer, N Nadarajah, K Perglerovà, T Haferlach and C Haferlach

Leukemia 2018 32: 295-302; advance online publication, July 28, 2017; 10.1038/leu.2017.239

Abstract | Full Text

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

T-C Teh, N-Y Nguyen, D M Moujalled, D Segal, G Pomilio, S Rijal, A Jabbour, K Cummins, K Lackovic, P Blombery, E Thompson, P G Ekert, G Lessene, S P Glaser, D C S Huang, A W Roberts, M A Guthridge and A H Wei

Leukemia 2018 32: 303-312; advance online publication, July 28, 2017; 10.1038/leu.2017.243

Abstract | Full Text

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia OPEN

K Reiter, H Polzer, C Krupka, A Maiser, B Vick, M Rothenberg-Thurley, K H Metzeler, D Dörfel, H R Salih, G Jung, E Nößner, I Jeremias, W Hiddemann, H Leonhardt, K Spiekermann, M Subklewe and P A Greif

Leukemia 2018 32: 313-322; advance online publication, August 14, 2017; 10.1038/leu.2017.257

Abstract | Full Text

ACUTE LYMPHOBLASTIC LEUKEMIA

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis

P Garrido Castro, E H J van Roon, S S Pinhanços, L Trentin, P Schneider, M Kerstjens, G te Kronnie, O Heidenreich, R Pieters and R W Stam

Leukemia 2018 32: 323-331; advance online publication, July 10, 2017; 10.1038/leu.2017.216

Abstract | Full Text

CHRONIC LYMPHOCYTIC LEUKEMIA

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups OPEN

A Burns, R Alsolami, J Becq, B Stamatopoulos, A Timbs, D Bruce, P Robbe, D Vavoulis, R Clifford, M Cabes, H Dreau, J Taylor, S J L Knight, R Mansson, D Bentley, R Beekman, J I Martín-Subero, E Campo, R S Houlston, K E Ridout and A Schuh

Leukemia 2018 32: 332-342; advance online publication, June 6, 2017; 10.1038/leu.2017.177

Abstract | Full Text

LYMPHOMA

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells

B Sun, W Fiskus, Y Qian, K Rajapakshe, K Raina, K G Coleman, A P Crew, A Shen, D T Saenz, C P Mill, A J Nowak, N Jain, L Zhang, M Wang, J D Khoury, C Coarfa, C M Crews and K N Bhalla

Leukemia 2018 32: 343-352; advance online publication, June 30, 2017; 10.1038/leu.2017.207

Abstract | Full Text

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

Z Yao, L Deng, Z Y Xu-Monette, G C Manyam, P Jain, A Tzankov, C Visco, G Bhagat, J Wang, K Dybkaer, W Tam, E D Hsi, J H van Krieken, M Ponzoni, A J M Ferreri, M B Møller, J N Winter, M A Piris, L Fayad, Y Liu, Y Song, R Z Orlowski, H Kantarjian, L J Medeiros, Y Li, J Cortes and K H Young

Leukemia 2018 32: 353-363; advance online publication, July 12, 2017; 10.1038/leu.2017.222

Abstract | Full Text

Lamin B1 regulates somatic mutations and progression of B-cell malignancies OPEN

T Klymenko, J Bloehdorn, J Bahlo, S Robrecht, G Akylzhanova, K Cox, S Estenfelder, J Wang, J Edelmann, J C Strefford, T K Wojdacz, K Fischer, M Hallek, S Stilgenbauer, M Cragg, J Gribben and A Braun

Leukemia 2018 32: 364-375; advance online publication, August 14, 2017; 10.1038/leu.2017.255

Abstract | Full Text

MULTIPLE MYELOMA, GAMMOPATHIES

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients OPEN

M Michallet, C Chapuis-Cellier, T Dejoie, C Lombard, H Caillon, M Sobh, P Moreau, M Attal and H Avet-Loiseau

Leukemia 2018 32: 376-382; advance online publication, June 30, 2017; 10.1038/leu.2017.209

Abstract | Full Text

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

H Goldschmidt, H M Lokhorst, E K Mai, B van der Holt, I W Blau, S Zweegman, K C Weisel, E Vellenga, M Pfreundschuh, M J Kersten, C Scheid, S Croockewit, R Raymakers, D Hose, A Potamianou, A Jauch, J Hillengass, M Stevens-Kroef, M S Raab, A Broijl, H W Lindemann, G M J Bos, P Brossart, M van Marwijk Kooy, P Ypma, U Duehrsen, R M Schaafsma, U Bertsch, T Hielscher, Le Jarari, H J Salwender and P Sonneveld

Leukemia 2018 32: 383-390; advance online publication, July 4, 2017; 10.1038/leu.2017.211

Abstract | Full Text

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma OPEN

A Besse, S C Stolze, L Rasche, N Weinhold, G J Morgan, M Kraus, J Bader, H S Overkleeft, L Besse and C Driessen

Leukemia 2018 32: 391-401; advance online publication, July 5, 2017; 10.1038/leu.2017.212

Abstract | Full Text

A compound chimeric antigen receptor strategy for targeting multiple myeloma OPEN

K H Chen, M Wada, K G Pinz, H Liu, X Shuai, X Chen, L E Yan, J C Petrov, H Salman, L Senzel, E L H Leung, X Jiang and Y Ma

Leukemia 2018 32: 402-412; advance online publication, September 27, 2017; 10.1038/leu.2017.302

Abstract | Full Text

MYELODYSPLASTIC SYNDROME

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia OPEN

V Santini, B Allione, G Zini, D Gioia, M Lunghi, A Poloni, D Cilloni, A Sanna, E Masiera, M Ceccarelli, O Abdel-Wahab, A Terenzi, E Angelucci, C Finelli, F Onida, A Pelizzari, D Ferrero, G Saglio, M Figueroa and A Levis

Leukemia 2018 32: 413-418; advance online publication, June 13, 2017; 10.1038/leu.2017.186

Abstract | Full Text

High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis

K C Kawabata, Y Hayashi, D Inoue, H Meguro, H Sakurai, T Fukuyama, Y Tanaka, S Asada, T Fukushima, R Nagase, R Takeda, Y Harada, J Kitaura, S Goyama, H Harada, H Aburatani and T Kitamura

Leukemia 2018 32: 419-428; advance online publication, July 19, 2017; 10.1038/leu.2017.227

Abstract | Full Text

CHRONIC MYELOPROLIFERATIVE NEOPLASMS

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

M O Holmström, E Martinenaite, S M Ahmad, Ö Met, C Friese, L Kjær, C H Riley, P thor Straten, I M Svane, H C Hasselbalch and M H Andersen

Leukemia 2018 32: 429-437; advance online publication, July 5, 2017; 10.1038/leu.2017.214

Abstract | Full Text

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients OPEN

S Ruberti, E Bianchi, P Guglielmelli, S Rontauroli, G Barbieri, L Tavernari, T Fanelli, R Norfo, V Pennucci, G Corbizi Fattori, C Mannarelli, N Bartalucci, B Mora, L Elli, M A Avanzini, C Rossi, S Salmoiraghi, R Zini, S Salati, Z Prudente, V Rosti, F Passamonti, A Rambaldi, S Ferrari, E Tagliafico, A M Vannucchi and R Manfredini on behalf of the AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) Investigators

Leukemia 2018 32: 438-449; advance online publication, July 12, 2017; 10.1038/leu.2017.220

Abstract | Full Text

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status OPEN

B Kubesova, S Pavlova, J Malcikova, J Kabathova, L Radova, N Tom, B Tichy, K Plevova, B Kantorova, K Fiedorova, M Slavikova, V Bystry, J Kissova, B Gisslinger, H Gisslinger, M Penka, J Mayer, R Kralovics, S Pospisilova and M Doubek

Leukemia 2018 32: 450-461; advance online publication, July 24, 2017; 10.1038/leu.2017.230

Abstract | Full Text

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms OPEN

H Zhan, C H S Lin, Y Segal and K Kaushansky

Leukemia 2018 32: 462-469; advance online publication, July 24, 2017; 10.1038/leu.2017.233

Abstract | Full Text

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial

D J DeAngelo, T I George, A Linder, C Langford, C Perkins, J Ma, P Westervelt, J D Merker, C Berube, S Coutre, M Liedtke, B Medeiros, D Sternberg, C Dutreix, P-A Ruffie, C Corless, T J Graubert and J Gotlib

Leukemia 2018 32: 470-478; advance online publication, July 24, 2017; 10.1038/leu.2017.234

Abstract | Full Text

STEM CELL BIOLOGY

Transforming growth factor-β1 regulates the nascent hematopoietic stem cell niche by promoting gluconeogenesis

C-Y Zhang, H-M Yin, H Wang, D Su, Y Xia, L-F Yan, B Fang, W Liu, Y-M Wang, A-H Gu and Y Zhou

Leukemia 2018 32: 479-491; advance online publication, June 23, 2017; 10.1038/leu.2017.198

Abstract | Full Text

STEM CELL TRANSPLANTATION

Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants

Y Wang, D-P Wu, Q-F Liu, L-P Xu, K-Y Liu, X-H Zhang, Y Xu, F Huang and X-J Huang

Leukemia 2018 32: 492-498; advance online publication, June 23, 2017; 10.1038/leu.2017.199

Abstract | Full Text

MOLECULAR TARGETS FOR THERAPY

Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML

S Kaushik, F Liu, K J Veazey, G Gao, P Das, L F Neves, K Lin, Y Zhong, Y Lu, V Giuliani, M T Bedford, S D Nimer and M A Santos

Leukemia 2018 32: 499-509; advance online publication, June 30, 2017; 10.1038/leu.2017.206

Abstract | Full Text

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia

L Angenendt, S Reuter, D Kentrup, A S Benk, F Neumann, J Hüve, A C Martens, C Schwöppe, T Kessler, L H Schmidt, T Sauer, C Brand, J-H Mikesch, G Lenz, R M Mesters, C Müller-Tidow, W Hartmann, E Wardelmann, D Neri, W E Berdel, C Roesli and C Schliemann

Leukemia 2018 32: 510-519; advance online publication, June 30, 2017; 10.1038/leu.2017.208

Abstract | Full Text

IMMUNOTHERAPY

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, J Orange, X Wan, X Lu, A Reynolds, M Gagea, P Banerjee, R Cai, M H Bdaiwi, R Basar, M Muftuoglu, L Li, D Marin, W Wierda, M Keating, R Champlin, E Shpall and K Rezvani

Leukemia 2018 32: 520-531; advance online publication, July 20, 2017; 10.1038/leu.2017.226

Abstract | Full Text

CYTOGENETICS AND MOLECULAR GENETICS

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia

Q Zhang, M C Ball, Y Zhao, M Balasis, C Letson, A Vedder, A F List, P K Epling-Burnette, R S Komrokji and E Padron

Leukemia 2018 32: 532-538; advance online publication, June 21, 2017; 10.1038/leu.2017.184

Abstract | Full Text

Letters to the Editor

Top

Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia

S Jo, J H Lee, J J Mattei, D M Barrett, P van den Elzen, S A Grupp, G S D Reid and A E Seif

Leukemia 2018 32: 539-542; advance online publication, September 19, 2017; 10.1038/leu.2017.290

Full Text

Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile

I Del Giudice, G M Rigolin, S Raponi, L Cafforio, C Ilari, J Wang, M Bordyuh, A Piciocchi, M Marinelli, M Nanni, S Tavolaro, M Filetti, A Bardi, E Tammiso, E Volta, M Negrini, E Saccenti, F R Mauro, D Rossi, G Gaidano, A Guarini, R Rabadan, A Cuneo and R Foà

Leukemia 2018 32: 543-546; advance online publication, September 19, 2017; 10.1038/leu.2017.292

Full Text

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies

E Casey, S Bournazos, G Mo, P Mondello, K S Tan, J V Ravetch and D A Scheinberg

Leukemia 2018 32: 547-549; advance online publication, September 19, 2017; 10.1038/leu.2017.293

Full Text

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms

S K Balasubramanian, M Aly, Y Nagata, T Bat, B P Przychodzen, C M Hirsch, V Adema, V Visconte, T Kuzmanovic, T Radivoyevitch, A Nazha, S Mukherjee, M A Sekeres and J P Maciejewski

Leukemia 2018 32: 550-553; advance online publication, September 22, 2017; 10.1038/leu.2017.295

Full Text

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis

J-C Hernández-Boluda, A Pereira, J-G Correa, A Alvarez-Larrán, F Ferrer-Marín, J-M Raya, J Martínez-López, M Pérez-Encinas, N Estrada, P Velez, M-L Fox, V García-Gutiérrez, A Payer, A Kerguelen, B Cuevas, M-A Durán, M-J Ramírez, M-T Gómez-Casares, M-I Mata-Vázquez, E Mora, C Martínez-Valverde, M Gómez and F Cervantes on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)

Leukemia 2018 32: 553-555; advance online publication, September 22, 2017; 10.1038/leu.2017.297

Full Text

Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2

S Bartels, M Faisal, G Büsche, J Schlue, H Kreipe and U Lehmann

Leukemia 2018 32: 556-558; advance online publication, September 22, 2017; 10.1038/leu.2017.298

Full Text

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

G Kerdivel, V Chesnais, E Becht, A Toma, N Cagnard, F Dumont, A Rousseau, P Fenaux, S Chevret, N Chapuis, V Boeva, W H Fridman, M Fontenay and O Kosmider on behalf of the Groupe Francophone des Myélodysplasies

Leukemia 2018 32: 558-562; advance online publication, October 3, 2017; 10.1038/leu.2017.305

Full Text

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia OPEN

M S Topp, M Stelljes, G Zugmaier, P Barnette, L T Heffner, Jr, T Trippett, J Duell, R C Bargou, C Holland, J E Benjamin, M Klinger and M R Litzow

Leukemia 2018 32: 562-565; advance online publication, October 9, 2017; 10.1038/leu.2017.306

Full Text

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma

G Hu, S Dasari, Y W Asmann, P T Greipp, R A Knudson, H K Benson, Y Li, B W Eckloff, J Jen, B K Link, L Jiang, J S Sidhu, L E Wellik, T E Witzig, N N Bennani, J R Cerhan, R L Boddicker and A L Feldman

Leukemia 2018 32: 565-569; advance online publication, October 13, 2017; 10.1038/leu.2017.309

Full Text

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients OPEN

T K Bera, Y Abe, T Ise, A Oberle, D Gallardo, X-f Liu, S Nagata, M Binder and I Pastan

Leukemia 2018 32: 569-572; advance online publication, November 17, 2017; 10.1038/leu.2017.315

Full Text

Corrigenda

Top

miR-194-5p/BCLAF1 deregulation in AML tumorigenesis

C Dell'Aversana, C Giorgio, L D'Amato, G Lania, F Matarese, S Saeed, A Di Costanzo, V Belsito Petrizzi, C Ingenito, J H A Martens, I Pallavicini, S Minucci, A Carissimo, H G Stunnenberg and L Altucci

Leukemia 2018 32: 573; advance online publication, December 22, 2017; 10.1038/leu.2017.310

Full Text

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups OPEN

A Burns, R Alsolami, J Becq, B Stamatopoulos, A Timbs, D Bruce, P Robbe, D Vavoulis, R Clifford, M Cabes, H Dreau, J Taylor, S J L Knight, R Mansson, D Bentley, R Beekman, J I Martín-Subero, E Campo, R S Houlston, K E Ridout and A Schuh

Leukemia 2018 32: 573; advance online publication, November 21, 2017; 10.1038/leu.2017.311

Full Text

Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia

S Jo, J H Lee, J J Mattei, D M Barrett, P van den Elzen, S A Grupp, G S D Reid and A E Seif

Leukemia 2018 32: 574; advance online publication, January 5, 2018; 10.1038/leu.2017.312

Full Text

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches OPEN

S Pearson, A J K Williamson, R Blance, T C P Somervaille, S Taylor, N Azadbakht, A D Whetton and A Pierce

Leukemia 2018 32: 574; advance online publication, December 19, 2017; 10.1038/leu.2017.333

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature